5'-Guanidinonaltrindol

5'-Guanidinonaltrindol
(IUPAC) ime
	5'-Guanidinyl-17-(cyclopropylmethyl)-6,7-dehydro-4,5α-epoxy-3,14-dihydroxy-6,7-2',3'-indolomorphinan
Klinički podaci
Identifikatori
ATC kod	nije dodeljen
PubChem	6604846
ChEMBL	CHEMBL330427
Hemijski podaci
Formula	C27H29N5O3
Mol. masa	471,550 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C27H29N5O3/c28-25(29)30-15-4-5-18-16(10-15)17-11-27(34)20-9-14-3-6-19(33)23-21(14)26(27,24(35-23)22(17)31-18)7-8-32(20)12-13-1-2-13/h3-6,10,13,20,24,31,33-34H,1-2,7-9,11-12H2,(H4,28,29,30) ; Key: VLNHDKDBGWXJEE-UHFFFAOYSA-N
Sinonimi	5'-Guanidinonaltrindol, GNTI
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

5'-Guanidinonaltrindol (GNTI) je opioidni antagonist koji se koristi u naučnim istraživanjima. On je veoma selektivan za κ opioidni receptor. On je pet puta pontentniji i 500 puta selektivniji od obično korištenog κ-opioidnog antagonista norbinaltorfimina.^[4] On ima spor početak i dugo trajanje dejstva,^[5]^[6] i proizvodi antidepresantske efekte u životinjskim studijama.^[7] GNTI takođe povišava alodiniju putem ometanja κ-opioidnog peptida dinorfina.^[8]

Literatura

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Jones, RM; Portoghese, PS (2000). „5'-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist”. European journal of pharmacology 396 (1): 49–52. PMID 10822054.
↑ Negus, SS; Mello, NK; Linsenmayer, DC; Jones, RM; Portoghese, PS (2002). „Kappa opioid antagonist effects of the novel kappa antagonist 5'-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys”. Psychopharmacology 163 (3-4): 412–9. DOI:10.1007/s00213-002-1038-x. PMID 12373442.
↑ Bruchas, MR; Yang, T; Schreiber, S; Defino, M; Kwan, SC; Li, S; Chavkin, C (2007). „Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase”. The Journal of biological chemistry 282 (41): 29803–11. DOI:10.1074/jbc.M705540200. PMC 2096775. PMID 17702750.
↑ Mague, SD; Pliakas, AM; Todtenkopf, MS; Tomasiewicz, HC; Zhang, Y; Stevens Jr, WC; Jones, RM; Portoghese, PS i dr.. (2003). „Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats”. The Journal of pharmacology and experimental therapeutics 305 (1): 323–30. DOI:10.1124/jpet.102.046433. PMID 12649385.
↑ Obara, I; Mika, J; Schafer, MK; Przewlocka, B (2003). „Antagonists of the kappa-opioid receptor enhance allodynia in rats and mice after sciatic nerve ligation”. British journal of pharmacology 140 (3): 538–46. DOI:10.1038/sj.bjp.0705427. PMC 1574046. PMID 12970097.

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[4] Jones, RM; Portoghese, PS (2000). „5'-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist”. European journal of pharmacology 396 (1): 49–52. PMID 10822054.

[5] Negus, SS; Mello, NK; Linsenmayer, DC; Jones, RM; Portoghese, PS (2002). „Kappa opioid antagonist effects of the novel kappa antagonist 5'-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys”. Psychopharmacology 163 (3-4): 412–9. DOI:10.1007/s00213-002-1038-x. PMID 12373442.

[6] Bruchas, MR; Yang, T; Schreiber, S; Defino, M; Kwan, SC; Li, S; Chavkin, C (2007). „Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase”. The Journal of biological chemistry 282 (41): 29803–11. DOI:10.1074/jbc.M705540200. PMC 2096775. PMID 17702750.

[7] Mague, SD; Pliakas, AM; Todtenkopf, MS; Tomasiewicz, HC; Zhang, Y; Stevens Jr, WC; Jones, RM; Portoghese, PS i dr.. (2003). „Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats”. The Journal of pharmacology and experimental therapeutics 305 (1): 323–30. DOI:10.1124/jpet.102.046433. PMID 12649385.

[8] Obara, I; Mika, J; Schafer, MK; Przewlocka, B (2003). „Antagonists of the kappa-opioid receptor enhance allodynia in rats and mice after sciatic nerve ligation”. British journal of pharmacology 140 (3): 538–46. DOI:10.1038/sj.bjp.0705427. PMC 1574046. PMID 12970097.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]